All News
EULAR26: Vasculitis updates: Glucorticoid use in AAV and GCA
EULAR recommends a combination of glucocorticoids with either rituximab or cyclophosphamide for remission induction in life-threatening or organ-threatening AAV, followed by gradual tapering of glucocorticoids.
Read Article
ICYMI: VEXAS Syndrome - A Review
Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies.
Read Article
ICYMI: EGPA Review
A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.
Read Article
EULAR26: Reports on Systemic Sclerosis
In an oral abstract presentation at EULAR 2026, results were shared from a longitudinal observational analysis of the EUSTAR database. The aim was to characterise organ involvement and disease progression – and time to these events – stratified by having a modified disease activity index (mDAI) score of less than 2.5 at baseline (inactive), versus those with 2.5 or higher (active).
Read Article
2-Gene Blood Test for Kawasaki Disease in Febrile Children
JAMA Network Open has publshed that a simple 2-gene blood test may aid the earlier diagnosis of Kawasaki disease in children with febrile illnesses.
Read Article
Do You Zoster Vaccinate? (6.19.2026)
Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.
Read Article
Late-Breaking Studies at EULAR 2026
Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical conc
Read Article
EULAR 2026 Rheumatology RoundUp
It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.
Read Article
What’s New in Macrophage Activation Syndrome Therapeutics
MAS, the most severe complication of Still’s disease, is increasingly recognized as a cytokine-driven hyperinflammatory state centered on interferon gamma (IFNγ). Therapeutic advances presented at EULAR 2026 demonstrate both consolidation of established pathways and expansion into novel biologic strategies.
Read Article
Day 4 EULAR Report
The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented.
Read Article
INDIGO: Switching B Cells Off, Not Out, in IgG4-Related Disease
B-cell targeting has moved to the centre of IgG4-related disease treatment, with inebilizumab, a CD19 depleter, as the recent benchmark. At EULAR 2026, INDIGO tested whether the disease can be controlled by switching B cells off rather than depleting them.
Read Article
Count Your Telangiectasias (5.29.2026)
Dr. Jack Cush reviews the news, journal articles and missed quiz questions.
Read Article
Links:
Links:
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2026 OP077 Another promising CAR-T in autoimmunity. In a Phase II study, Rap-Cel autologous CD19 CAR-T (shorter infusion time ~2d & low dose) vs traditional CAR-T showed drug-free improvement in N=6 #IIM & N=6 #SSc patients. Safety similar to other CAR-Ts @RheumNow https://t.co/byNn5X8JGh
Links:
